Breast tomosynthesis: a breast cancer screening tool
Purins A, Mundy L, Hiller JE
Record ID 32010000768
English
Authors' recommendations:
Tomosynthesis is not approved to date by the Food and Drug Administration (FDA). Most studies report that tomosynthesis and digital mammography are similar in diagnostic capability. Due to the reported reductions in radiation dose there may be some patient safety advantages to using tomosynthesis. No cost data were found regarding tomosynthesis. Although tomosynthesis may be used as an adjunct to digital mammography, it is unlikely that there will be a significant uptake of this technology in light of the recent roll out of, and the significant investment in, digital mammography in Australia. It is likely that tomosynthesis may be the next generation of technology used for breast screening but this will only occur once digital mammography equipment reaches a stage of natural attrition. Therefore HealthPACT have recommended that no further assessment of this technology is warranted.
Details
Project Status:
Completed
Year Published:
2009
URL for published report:
Not Available
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Australia
MeSH Terms
- Mass Screening
- Breast Diseases
- Breast Neoplasms
- Radiographic Image Enhancement
Contact
Organisation Name:
Adelaide Health Technology Assessment
Contact Address:
School of Public Health, Mail Drop 545, University of Adelaide, Adelaide SA 5005, AUSTRALIA, Tel: +61 8 8313 4617
Contact Name:
ahta@adelaide.edu.au
Contact Email:
ahta@adelaide.edu.au
Copyright:
Adelaide Health Technology Assessment (AHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.